Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Environ Toxicol Pharmacol. 2021 Jan 28;83:103599. doi: 10.1016/j.etap.2021.103599

Figure 2.

Figure 2.

Effects of inhibiting p44/42 and p38 MAPKs on TCS-induced IL-1β secretion from PBMCs. A) Fold change in TCS-stimulated Il-1β secretion from PBMCs when p44/42 was inhibited by 50 μM PD98059 (donor F630). B) Fold change in TCS-stimulated Il-1β secretion from PBMCs when p44/42 was inhibited by 50 μM PD98059 (donor F696). C) Fold change in TCS-stimulated Il-1β secretion from PBMCs when p38 was inhibited by 25 μM SB202190 (donor F630). D) Fold change in TCS-stimulated Il-1β secretion from PBMCs when p38 was inhibited by 25 μM SB202190 (donor F696). (+) indicates a significant increase compared to control and (*) indicates a significant decrease compared to appropriate control (no TCS or no TCS+inhibitor).